Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
Sign Up to like & getrecommendations! Published in 2017 at "Haematologica"
DOI: 10.3324/haematol.2016.160408
Abstract: Over the past decade, the survival of patients with multiple myeloma (MM) has dramatically improved. This remarkable change is largely due to an increase in the anti-myeloma armamentarium, including next generation proteasome inhibitors (carfilzomib, ixazomib),… read more here.
Keywords: sustained response; venetoclax therapy; myeloma; response venetoclax ... See more keywords
Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.833714
Abstract: B-cell receptor (BCR) signaling pathway and Bcl-2 family prosurvival proteins, specifically Bcl-2 and Mcl-1, are functional in the pathobiology of chronic lymphocytic leukemia (CLL). A pivotal and apical molecule in the BCR pathway is Bruton’s… read more here.
Keywords: amg 176; ibrutinib venetoclax; therapy; venetoclax ... See more keywords
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
Sign Up to like & getrecommendations! Published in 2022 at "Pathology and Oncology Research"
DOI: 10.3389/pore.2022.1610276
Abstract: Despite the introduction of novel agents, multiple myeloma remains incurable for most patients, necessitating further therapeutic options. Venetoclax, a selective BCL-2 inhibitor, had shown promising results in patients with translocation t(11;14), but questions remain open… read more here.
Keywords: venetoclax therapy; myeloma; targeted venetoclax; multiple myeloma ... See more keywords